论文部分内容阅读
波士顿消息:美国几家医院的研究人员研制出一种比组织胞浆素原活化剂(TPA)溶解血凝块更为有效的新药。领导这项研究的Bernard Statland称其为新的免疫纤维蛋白溶解疗法。这种药是由链激酶加上一种对交叉键纤维蛋白有特异性的单克隆抗体所组成。静脉注射后可被抗体引导到有血块的确切部位,对纤维蛋白有高度亲和性。链激酶的作用象往常一样是激活胞浆素原向胞浆素转化,然后胞浆
Boston News: Researchers at several US hospitals have developed a new drug that is more effective than tissue plasminogen activator (TPA) to dissolve blood clots. Bernard Statland, who led the study, called it a new immunofibrinolytic therapy. The drug consists of streptokinase plus a monoclonal antibody specific for cross-linked fibrin. After intravenous injection, the antibody can be guided to the exact site of the blood clot and has a high affinity for fibrin. The effect of streptokinase is to activate plasminogen conversion to plasmin, and then cytoplasm, as usual.